Amman, June 26 (Petra) - The Jordan Food and Drug Administration (JFDA) has confirmed that the batches of the "Semaglutide" preparation, branded as "Ozempic," available in the local market are approved and have successfully undergone rigorous laboratory procedures and tests, ensuring their quality, safety, and effectiveness.

Nizar Mhaidat, Director-General of the Administration, stated that the counterfeit formulations mentioned in a recent World Health Organization alert were not distributed in the Jordanian market.

He emphasized that the legally approved concentrations of the preparation, 0.25 mg, 0.5 mg, and 1 mg, are registered for the treatment of diabetes. However, its use for treating obesity and weight loss is not approved, and no clinical studies have been provided to support such usage.

Mhaidat highlighted that the JFDA continually emphasizes to relevant health authorities the importance of adhering to the approved indications for prescribing and dispensing the preparation. This ensures patient safety and the continued availability of medication for diabetic patients.